Jun Li, J., G. Chen, P. Ye, S. Wang, K. Zhang, W. Chen, S. M. Stepkowski, J. Li, S. Zhong, and J. Xia. 2011. CCR5 blockade in combination with cyclosporine increased cardiac graft survival and generated alternatively activated macrophages in primates. J. Immunol. 186: 3753–3761.
The image published in the second panel in Fig. 1C (CsA day 30) was mistakenly taken from the Control day 9 group instead of the CsA day 30 group. The correct image is published below; the entire figure is shown but the only change is to the second panel (CsA day 30) in Fig. 1C. The legend is correct as published and is shown below for reference.
![FIGURE 1. Effects of MVC therapy alone or in combination with CsA on heart allograft survival. A, The survival of heart allografts in recipients treated with an MVC and CsA combination was significantly prolonged to 240 d (p < 0.001 versus other groups). The survival of donor hearts in MVC alone, CsA alone, and control groups were 30, 30, and 9 d, respectively (n = 5/group). B, Acute rejection scores evaluated at day 30 in MVC/CsA group was lower (mean ± SD, 1.20 ± 0.45; median, 1) than in a control group at day 9 (mean ± SD, 2.80 ± 0.45; median, 3; p < 0.005). C, Histological images represent different experimental groups (H&E/elastic van Gieson [HE/EvG], original magnification ×100). D, Proliferative response of PBMCs from recipients 7 d posttransplant in MLR. E, IL-4, IL-13, and IFN-γ levels in a 48 h MLR measured in ELISPOT assays, which were performed in triplicates from each animal. Asterisks on the top of an error bar indicate statistically significant differences between this column and other columns in the same group, whereas asterisks on top of a line section indicate statistically significant difference between control group and MVC plus CsA-treated group. **p < 0.05, *p < 0.005. ND, not detectable.](https://aai.silverchair-cdn.com/aai/content_public/journal/jimmunol/191/6/10.4049_jimmunol.1390046/2/m_1390046fig01.jpeg?Expires=1682055413&Signature=uG0tNH6XNxAckk6q4yZ4mny8d2PZlaa1AArEMM6VvPJoNVSprWIEqTVuQPnu0h6vUyjEIxDYOTGbtaHV2AVuuMN30j1GhqRk2a0Q2dH8zW-zShtdJKlvSzwI6LkuF4GuW-VCY2tEpi6JPZ4I3nozxWUnbdRr4FGe7pLrnbgj4hJkzO8Jfj4rJx5e8kVfegMWIGaZyiGb5GbFeRyxy-dGaIynHuM8Ii4DYpyLzgqeenPcFKUKK7FVcVqkl6WM14pqOKDFV7PMM-x1B~vyjEl-oOaS4X5jakyG7HzH80za7eR2G7nRNwXe7Vq5A53jeQEyiNp0DV~WuzqnB4JWZWdXxA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Effects of MVC therapy alone or in combination with CsA on heart allograft survival. A, The survival of heart allografts in recipients treated with an MVC and CsA combination was significantly prolonged to 240 d (p < 0.001 versus other groups). The survival of donor hearts in MVC alone, CsA alone, and control groups were 30, 30, and 9 d, respectively (n = 5/group). B, Acute rejection scores evaluated at day 30 in MVC/CsA group was lower (mean ± SD, 1.20 ± 0.45; median, 1) than in a control group at day 9 (mean ± SD, 2.80 ± 0.45; median, 3; p < 0.005). C, Histological images represent different experimental groups (H&E/elastic van Gieson [HE/EvG], original magnification ×100). D, Proliferative response of PBMCs from recipients 7 d posttransplant in MLR. E, IL-4, IL-13, and IFN-γ levels in a 48 h MLR measured in ELISPOT assays, which were performed in triplicates from each animal. Asterisks on the top of an error bar indicate statistically significant differences between this column and other columns in the same group, whereas asterisks on top of a line section indicate statistically significant difference between control group and MVC plus CsA-treated group. **p < 0.05, *p < 0.005. ND, not detectable.
Effects of MVC therapy alone or in combination with CsA on heart allograft survival. A, The survival of heart allografts in recipients treated with an MVC and CsA combination was significantly prolonged to 240 d (p < 0.001 versus other groups). The survival of donor hearts in MVC alone, CsA alone, and control groups were 30, 30, and 9 d, respectively (n = 5/group). B, Acute rejection scores evaluated at day 30 in MVC/CsA group was lower (mean ± SD, 1.20 ± 0.45; median, 1) than in a control group at day 9 (mean ± SD, 2.80 ± 0.45; median, 3; p < 0.005). C, Histological images represent different experimental groups (H&E/elastic van Gieson [HE/EvG], original magnification ×100). D, Proliferative response of PBMCs from recipients 7 d posttransplant in MLR. E, IL-4, IL-13, and IFN-γ levels in a 48 h MLR measured in ELISPOT assays, which were performed in triplicates from each animal. Asterisks on the top of an error bar indicate statistically significant differences between this column and other columns in the same group, whereas asterisks on top of a line section indicate statistically significant difference between control group and MVC plus CsA-treated group. **p < 0.05, *p < 0.005. ND, not detectable.
In addition, we would like to clarify that the upper panel (CCR5&Arg1) in Fig. 5C is from animals treated with CsA and biopsied on day 30; this panel is identical to the left panel in the top row (CsA day 30) of Fig. 4A. The lower panel (CCR5&Mrc1) in Fig. 5C is from animals treated with MVC and biopsied on day 30; this panel is identical to the middle panel in the top row (MVC day 30) of Fig. 4A.
